{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:47:38Z","timestamp":1783648058783,"version":"3.55.0"},"reference-count":34,"publisher":"Archives of Endocrinology and Metabolism","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch. Endocrinol. Metab."],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1590\/2359-3997000000210","type":"journal-article","created":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T23:27:32Z","timestamp":1475969252000},"page":"479-485","source":"Crossref","is-referenced-by-count":19,"title":["Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response"],"prefix":"10.20945","volume":"60","author":[{"given":"Leandro","family":"Kasuki","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil; Instituto Estadual do C\u00e9rebro Paulo Niemeyer,  Brasil; Hospital Federal de Bonsucesso,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn de Oliveira","family":"Machado","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana Lumi","family":"Ogino","sequence":"additional","affiliation":[{"name":"Instituto Estadual do C\u00e9rebro Paulo Niemeyer,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Caroline Alves","family":"Coelho","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil; Hospital Pedro Ernesto,  Brasil; Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia Marques dos Santos","family":"Silva","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Eduardo Armondi","family":"Wildemberg","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil; Instituto Estadual do C\u00e9rebro Paulo Niemeyer,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Henrique Azeredo","family":"Lima","sequence":"additional","affiliation":[{"name":"Instituto Estadual do C\u00e9rebro Paulo Niemeyer,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica R.","family":"Gadelha","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil; Instituto Estadual do C\u00e9rebro Paulo Niemeyer,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao A","year":"2004","journal-title":"Endocr Rev"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway IM","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers OM","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson L","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1530\/eje.1.01863","article-title":"The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical \u201ccure\u201d","volume":"152","author":"Nomikos P","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed S","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","article-title":"A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly","volume":"66","author":"Mercado M","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2265.2008.03441.x","article-title":"Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study","volume":"70","author":"Colao A","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","article-title":"Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension","volume":"13","author":"Melmed S","year":"2010","journal-title":"Pituitary"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron PJ","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jc.2012-3072","article-title":"A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy","volume":"98","author":"Annamalai AK","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha MR","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao A","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-014-0183-4","article-title":"Cabergoline treatment in acromegaly: cons","volume":"46","author":"Kasuki L","year":"2014","journal-title":"Endocrine"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret L","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/s-0034-1389987","article-title":"Treatment outcome results from the Bulgarian Acromegaly Database: adjuvant dopamine agonist therapy is efficient in less than one fifth of non-irradiated patients","volume":"123","author":"Vandeva S","year":"2015","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1210\/jc.2008-1826","article-title":"Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly","volume":"94","author":"Neto LV","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1677\/JME-08-0162","article-title":"The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology","volume":"42","author":"Ferone D","year":"2009","journal-title":"J Mol Endocrinol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1530\/eje.0.148S021","article-title":"Discovery and mechanism of action of pegvisomant","volume":"148","author":"Kopchick JJ","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"16","key":"ref20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer PJ","year":"2000","journal-title":"N Engl J Med"},{"issue":"9295","key":"ref21","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely AJ","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely AJ","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/jc.2006-1412","article-title":"Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant","volume":"92","author":"Parkinson C","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s11102-015-0673-2","article-title":"Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort","volume":"18","author":"Sievers C","year":"2015","journal-title":"Pituitary"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11102-008-0157-8","article-title":"Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly","volume":"12","author":"Bianchi A","year":"2009","journal-title":"Pituitary"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1210\/jc.2009-1630","article-title":"The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly","volume":"95","author":"Bernabeu I","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"E165","DOI":"10.1210\/jc.2011-1769","article-title":"Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study","volume":"97","author":"Filopanti M","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1530\/EJE-15-0519","article-title":"Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the growth hormone receptor deletion of exon 3","volume":"173","author":"Franck SE","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ghir.2009.10.001","article-title":"Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR","volume":"20","author":"Lima GA","year":"2010","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance","volume":"154","author":"Colao A","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1530\/EJE-08-0705","article-title":"Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy","volume":"160","author":"Marazuela M","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s40618-015-0289-4","article-title":"Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience","volume":"38","author":"Cannavo S","year":"2015","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1210\/jc.2014-2032","article-title":"Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly","volume":"99","author":"Neggers SJ","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ghir.2011.03.004","article-title":"Combination treatment with somatostatin analogues and pegvisomant in acromegaly","volume":"21","author":"Neggers SJ","year":"2011","journal-title":"Growth Horm IGF Res"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/aem\/v60n5\/2359-3997-aem-2359-3997000000210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T16:20:16Z","timestamp":1527697216000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S2359-39972016000500479&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S2359-39972016000500479"],"URL":"https:\/\/doi.org\/10.1590\/2359-3997000000210","relation":{},"ISSN":["2359-3997"],"issn-type":[{"value":"2359-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}